4basebio

Historical price data

4basebio is an innovation-led biotechnology company with a mission to redefine genetic medicine by providing superior, synthetic DNA starting materials. Its core achievement is the development of the TruePrime® enzymatic platform, which enables faster, safer, and more scalable production of DNA compared to conventional bacterial fermentation. The company's strategy is dual-pronged: operating as a high-value supplier of GMP-grade synthetic DNA to pharmaceutical partners and developing its own non-viral delivery platform for therapeutic payloads. A key recent milestone is the entry of a partner's mRNA product, using 4basebio's opDNA®, into a Phase I/II clinical trial following FDA IND approval.

Proprietary, cell-free enzymatic DNA manufacturing platform (TruePrime®) that produces synthetic DNA (opDNA®) without bacterial sequences, offering faster, safer, and more scalable production than traditional plasmid DNA.

Competes against traditional plasmid DNA CDMOs (e.g., Aldevron, Charles River) and alternative synthetic DNA platforms (e.g., Touchlight Genetics). Differentiation lies in the proprietary TruePrime® enzyme system, focus on long fragments (up to 20kb), and recent clinical-stage validation.